A detailed history of Nomura Asset Management CO LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Nomura Asset Management CO LTD holds 1,041,036 shares of BMY stock, worth $53.9 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,041,036
Previous 1,036,665 0.42%
Holding current value
$53.9 Million
Previous $56.2 Million 23.1%
% of portfolio
0.15%
Previous 0.21%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $175,932 - $231,619
4,371 Added 0.42%
1,041,036 $43.2 Million
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $3.12 Million - $3.54 Million
65,074 Added 6.7%
1,036,665 $56.2 Million
Q4 2023

Feb 09, 2024

BUY
$48.48 - $57.85 $2.88 Million - $3.44 Million
59,486 Added 6.52%
971,591 $49.9 Million
Q3 2023

Nov 03, 2023

BUY
$57.89 - $64.73 $3.58 Million - $4 Million
61,811 Added 7.27%
912,105 $52.9 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $2.29 Million - $2.54 Million
35,937 Added 4.41%
850,294 $54.4 Million
Q1 2023

May 11, 2023

SELL
$65.71 - $74.53 $19.8 Million - $22.5 Million
-301,756 Reduced 27.04%
814,357 $56.4 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $10.3 Million - $12.2 Million
-150,954 Reduced 11.91%
1,116,113 $80.3 Million
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $18,764 - $11.1 Million
-144,344 Reduced 10.23%
1,267,067 $90.1 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $12.6 Million - $13.9 Million
-173,895 Reduced 10.97%
1,411,411 $109 Million
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $5.87 Million - $7.04 Million
95,519 Added 6.41%
1,585,306 $116 Million
Q4 2021

Feb 01, 2022

BUY
$53.63 - $62.52 $17.6 Million - $20.5 Million
327,324 Added 28.16%
1,489,787 $92.9 Million
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $319,162 - $373,858
5,394 Added 0.47%
1,162,463 $68.8 Million
Q2 2021

Aug 06, 2021

BUY
$61.91 - $67.42 $4.99 Million - $5.43 Million
80,543 Added 7.48%
1,157,069 $77.3 Million
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $1.93 Million - $2.17 Million
-32,467 Reduced 2.93%
1,076,526 $68 Million
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $3.21 Million - $3.64 Million
55,676 Added 5.29%
1,108,993 $68.8 Million
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $5.44 Million - $6.03 Million
94,681 Added 9.88%
1,053,317 $63.5 Million
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $22.3 Million - $26 Million
406,345 Added 73.57%
958,636 $56.4 Million
Q1 2020

May 14, 2020

BUY
$46.4 - $67.43 $2.46 Million - $3.57 Million
52,988 Added 10.61%
552,291 $30.8 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $535,109 - $698,002
10,874 Added 2.23%
499,303 $32.1 Million
Q3 2019

Nov 13, 2019

BUY
$42.77 - $50.71 $486,808 - $577,181
11,382 Added 2.39%
488,429 $24.8 Million
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $551,101 - $609,398
-12,351 Reduced 2.52%
477,047 $21.6 Million
Q1 2019

May 10, 2019

BUY
$45.12 - $53.8 $146,910 - $175,172
3,256 Added 0.67%
489,398 $23.3 Million
Q4 2018

Feb 12, 2019

BUY
$48.76 - $63.23 $10.2 Million - $13.2 Million
208,646 Added 75.19%
486,142 $25.3 Million
Q3 2018

Nov 07, 2018

BUY
$55.19 - $62.25 $690,371 - $778,685
12,509 Added 4.72%
277,496 $17.2 Million
Q2 2018

Aug 03, 2018

SELL
$50.53 - $62.98 $336,075 - $418,879
-6,651 Reduced 2.45%
264,987 $14.7 Million
Q1 2018

May 14, 2018

BUY
$59.92 - $68.98 $470,551 - $541,699
7,853 Added 2.98%
271,638 $17.2 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $438,640 - $478,231
7,318 Added 2.85%
263,785 $16.2 Million
Q3 2017

Nov 13, 2017

SELL
$55.23 - $63.74 $929,631 - $1.07 Million
-16,832 Reduced 6.16%
256,467 $16.3 Million
Q2 2017

Aug 14, 2017

BUY
N/A
273,299
273,299 $15.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $110B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Nomura Asset Management CO LTD Portfolio

Follow Nomura Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Asset Management CO LTD with notifications on news.